TY - JOUR AU - Mosegui, Gabriela Bittencourt Gonzalez AU - Vianna, Cid Manso De Mello AU - Rodrigues, Marcus Paulo Da Silva AU - Da Costa, Talita Martins Alves AU - Valle, Paula Medeiros Do PY - 2017/06/01 Y2 - 2024/03/29 TI - COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE IN THE TREATMENT OF METASTATIC BREAST CANCER JF - International Journal of Pharmacy and Pharmaceutical Sciences JA - Int J Pharm Pharm Sci VL - 9 IS - 6 SE - Original Article(s) DO - 10.22159/ijpps.2017v9i6.18741 UR - https://journals.innovareacademics.in/index.php/ijpps/article/view/18741 SP - 155-160 AB - <p><strong>Objective: </strong>To investigate the cost-effectiveness of second-line pharmacological treatments for metastatic breast cancer (MBC) by comparing trastuzumab emtansine (T-DM1) versus a combination of lapatinib and capecitabine (LAP+CAP) from the perspective of the Brazilian health system, the Unified Health System (Sistema Único de Saúde–SUS).</p><p><strong>Methods: </strong>The results of each treatment were simulated based on a three-state Markov decision model applied to a hypothetical cohort of 1,000 women, aged 50 y old or older, with MBC and HER2 (human epidermal growth factor receptor 2) overexpression. The data on the effectiveness of treatments were taken from reports in the literature. The period considered for simulation was three years subdivided into monthly cycles of transition between health states. A discount rate of 5% per year was applied to costs and outcomes. Possible uncertainty was assessed by means of a sensitivity analysis.</p><p><strong>Results: </strong>Chemotherapy for women with refractory MBC using T-DM1 monotherapy was ruled out by extended dominance. Treatment with LAP+CAP proved to be the most efficient strategy because the cost in relation to the overall survival (BRL 72,035.43/quality-adjusted life year–QALY) was the lowest and fell within the acceptability threshold, BRL 86,628.00.</p><p><strong>Conclusion: </strong>T-DM1 demonstrated pharmacological superiority over other agents used for the treatment of MBC in clinical studies. However, the price set for T-DM1 in Brazil is the determinant variable that contraindicates its inclusion in the SUS, in agreement with other international assessments.</p> ER -